Please assess the completion status of the following clinical trial:

Trial Title: Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Have at least 6 months history of GERD~* Continuously treated during the last 4 weeks before enrolment with daily optimized unchanged PPI therapy for any GERD indication~Exclusion Criteria:~* Patients that have not experienced any GERD symptom improvement at all during PPI treatment~* Prior surgery of the upper gastrointestinal tract.~* Subject who have any of the following conditions or diseases: Heart disease, Angina, Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 60 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 60 mg bid
- 120 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 120 mg bid
- 180 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 180 mg bid
- 240 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 240 mg bid
- Placebo (Type: PLACEBO_COMPARATOR): PPI+ Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).